<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01598337</url>
  </required_header>
  <id_info>
    <org_study_id>PSCC002CT</org_study_id>
    <nct_id>NCT01598337</nct_id>
  </id_info>
  <brief_title>The Effect Of Antiplatelets Therapy On Saphenous Vein Coronary Artery Bypass Graft Patency</brief_title>
  <official_title>The Effect Of Antiplatelets Therapy, Tirafiban, Prasugrel, And Aspirin On Saphenous Vein Coronary Artery Bypass Graft Patency</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Prince Sultan Cardiac Center, Adult Cardiology Department.</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Prince Sultan Cardiac Center, Adult Cardiology Department.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This protocol is designed to evaluate the effect of antiplatelets (Tirafiban and Prasugrel)
      on the incidence of early and intermediate graft patency after CABG.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Coronary artery bypass graft (CABG) surgery is a commonly used revascularization strategy in
      patients with severe coronary artery disease. Saphenous vein grafts (SVGs) are the most
      frequently used conduits for this procedure. Unlike arterial grafts, SVGs are particularly
      susceptible to occlusive thrombosis during the first post-operative year, which exposes
      patients to increased risks of death, myocardial infarction, and repeat revascularization.

      This study is designed to evaluate the effect of antiplatelets (Tirafiban and Prasugrel) on
      the incidence of early and intermediate graft patency after CABG. Patients will undergo
      planned cardiac Computed tomographic angiography (CTA) predischarge (at 1 week) and
      CTA/coronary angiography (CAG) at 6 months to 1 year follow-up. CTA at baseline
      (predischarge) and follow-up CTA/CAG at 6-12 months after CABG will be used to evaluate graft
      patency.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>April 2011</start_date>
  <primary_completion_date type="Anticipated">December 2013</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Venous graft patency</measure>
    <time_frame>At one year</time_frame>
    <description>Venous graft patency as assessed by computed tomographic angiography or coronary angiography</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Major cardiac events (MACE)</measure>
    <time_frame>At one year</time_frame>
    <description>Acute myocardial infarction (AMI), Stroke, minor bleeding, death, rate of revascularization</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Coronary Artery Disease</condition>
  <arm_group>
    <arm_group_label>Aspirin alone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Tirofoban</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patient assigned to this arm will receive tirofiban infusion starting approximately six hours post bypass surgery once hemomstasis established and no evidence of bleeding</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Clopidogrel</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive oral clopidogrel 75 mg 6-8 hours before coronary bypass surgery and continue daily mentenance dose as per instruction by investigators</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Prasugrel</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients started on prasugrel 6 hours post surgery 10 mg then continue on daily 10mg as per instruction by investigators</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aspirin</intervention_name>
    <description>Patients continue their maintenance dose not inturrupted by surgery , 81 mg daily</description>
    <arm_group_label>Aspirin alone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tirofiban</intervention_name>
    <description>Tirofiban infusion as specified by investigators to start after hemostasis been established</description>
    <arm_group_label>Aspirin alone</arm_group_label>
    <arm_group_label>Tirofoban</arm_group_label>
    <arm_group_label>Clopidogrel</arm_group_label>
    <arm_group_label>Prasugrel</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clopidogrel</intervention_name>
    <description>75 mg orally started 6-8hours before surgery</description>
    <arm_group_label>Aspirin alone</arm_group_label>
    <arm_group_label>Tirofoban</arm_group_label>
    <arm_group_label>Clopidogrel</arm_group_label>
    <arm_group_label>Prasugrel</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prasugrel</intervention_name>
    <description>10 mg daily as per instructions of investigators</description>
    <arm_group_label>Aspirin alone</arm_group_label>
    <arm_group_label>Tirofoban</arm_group_label>
    <arm_group_label>Clopidogrel</arm_group_label>
    <arm_group_label>Prasugrel</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  All comer study where all patients undergoing coronary bypass surgery (CABG) will be
             randomized to one of the four treatment groups

        Exclusion Criteria:

          -  Acute myocardial infarction (AMI) or cardiogenic shock

          -  Aortic dissection

          -  Mechanical valves.

          -  Contraindication to antiplatelets or aggrastat.

          -  Active bleeding or high risk of bleeding.

          -  History of hemorrhagic stroke any time.

          -  Recent history of embolic stroke or transient ischemic attack (TIA) less than 3
             months.

          -  Active peptic ulcer disease (PUD).

          -  Liver derangement.

          -  Warfarin use.

          -  Heparin-induced thrombocytopenia (HIT) syndrome.

          -  Thrombocytopenia (platelet count &lt;100,000/mm3), disorders of platelet function
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hussein S Al-Amri, MD</last_name>
    <role>Study Director</role>
    <affiliation>Prince Sultan Cardiac Center (PSCC), Riyadh</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Prince Sultan Cardiac Center</name>
      <address>
        <city>Riyadh</city>
        <country>Saudi Arabia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hussein S Alamri, MD</last_name>
      <email>amriheart@hotmail.com</email>
    </contact>
    <investigator>
      <last_name>Antonio Calafiore</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Hussein S Alamri, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Abdulrahman M almoghairi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Saudi Arabia</country>
  </location_countries>
  <verification_date>May 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 9, 2012</study_first_submitted>
  <study_first_submitted_qc>May 14, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 15, 2012</study_first_posted>
  <last_update_submitted>May 14, 2012</last_update_submitted>
  <last_update_submitted_qc>May 14, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 15, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Prince Sultan Cardiac Center, Adult Cardiology Department.</investigator_affiliation>
    <investigator_full_name>Abdulrahman Al-Moghairi</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aspirin</mesh_term>
    <mesh_term>Tirofiban</mesh_term>
    <mesh_term>Clopidogrel</mesh_term>
    <mesh_term>Prasugrel Hydrochloride</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

